Replies to post #27345 on Seelos Therapeutics Inc (SEEL)

[PuuliTuku]

Yes I am serious.
Good discussion oldtimer.

20 million shares then.

I go with option A because Allergan wants its ED drug, dont you think FDA is gonna come down on ED-product health problems sooner or later?
And 10% marketshare sounds realistic to me so 35m royalties/year.

Why do you say their spendings/quarter will explode after vitaros approval? Minimal personnel, vitaros not taking resources anymore, they have stated they will not go forward with any other drugs without bigger partner.
If vitaros gets approved, ddaip hcl gets approved for human use, Im sure you are familiar with its ability to enchance drugs effect by making it more effective passing thru the skin. If I was on my home computer I could link some articles. Thats why I think outlicensing to right company could bring extra revenues.

PuuliTuku

[eicoman]

The question is, Why would a huge growing company like Allergan be interested in a small niche product like Vitaros, which they owned and did nothing with till Pascoe came knocking ? Is Allergan interested in DDAIP, Rayva, DDAIP and minoxidil ? Or did they just think what do they have to lose ?

If they opt in for the marketing it only makes sense that they buyout Apri and get the $100M plus tax write off for Apri's losses over the last 10 years. By that standard Apri is worth at least $5 a share for the tax benefit. Selling the company is the only value here to Apricus owners, so the question is not what share price it can achieve but what sale price can it achieve, what premium over $5 can they get?, between $5 and $10, maybe.

The NDA should be submitted soon, maybe by end of AUG., and they will try to get Allergan to commit before the approval decision, so they can line up another partner for a launch or buyout, imo.